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Bronchoalveolar lavage (BAL) studies in 20 patients at Bhopal. 1.3 ± 0.4 yr and 2.7 ± 0.6 yr after toxic gas
exposure had revealed that the lower respiratory tract inflammation had progressed from initial macrophage
alveolitis to macrophage-neutrophilic alveolitis. The interval between the two lavages was 1.4 ±  0.6 yr. BAL
studies in a new group of 14 patients 5.1 ± 1.0 yr after exposure had confirmed chronic inflammation of the
lower respiratory tract as evidenced by macrophage-neutrophilic alveolitis in these subjects as well. Clinical.
radiographic and pulmonary function abnormalities were persistent in a proportion of subjects in both
groups.
Fibronectin (FN) levels were estimated in BAL fluid in 41 patients. Elevated FN levels were seen in 12
(29.3%) subjects and nine of these 12 had radiographic abnormalities. Severely exposed subjects (n=30) had
significantly higher BAL fibronectin levels compared to normal subjects and mild/moderately exposed
subjects. Repeat FN estimations in BAL samples from 10 patients had revealed that five had abnormally high
FN including three who had high FN on both occasions. The number of patients showing abnormal decline
in pulmonary function was higher in patients with elevated FN than in patients with normal FN.
Thus, persisting clinical, roentgenographic and ventilatory abnormalities, as well as macrophage-
neutrophilic alveolitisalong with abnormally elevated FN levels in a proportion of subjects, suggest the
possibility that lung fibrosis can occur in subjects exposed to toxic gas at Bhopal.
Introduction
Bronchoalveolar lavage (BAL) studies in toxic
gas exposed subjects 1.5 ± 0.6 yr after exposure
(1985-1987) had revealed that there was a subclinical
alveolitis characterized by accumulation of macro-
phages in the lower respiratory tract, especially in
severely exposed subjects (1). It was not certain from
this study whether the inflammatory cells recovered
from the lower respiratory tract were activated; and if
so, is there any evidence of release of markers of
activity such as fibronectin (FN) by these cells into
the lavage fluid? It is possible that the macrophage
alveolitis may have spontaneous remission, as it had
been shown in pneumoconiosis that initial macro-
phage alveolitis did not necessarily lead to interstitial
fibrosis (2). However, there is also a possibility that
the cells comprisingalveolitis may release toxic
mediators (3), resulting in injury and fibrosis to lung
parenchyma. A study was. therefore, planned to
investigate the fate of alveolitis in patients from the
first study (1) by relavaging them 2.7 ± 0.6 yr (1987-
1989) after exposure and also to evaluate changes in
the lower respiratory tract in a new group of patients
5.1± 1.0 yr (1988-1991) after exposure. The study
was further utilized to investigate the presence of
markers of activity from inflammatory cells by
estimating FN concentrations in BAL fluid.
Subjects and Methods
This study involving 44 patients was done 2-7 yr
(1987-1991) after exposure to the toxic gas. All
studies were carried out under protocols approved by
the Indian Council of Medical Research, New Delhi.
Informed consent was obtained from each subject
after explaining the procedure in local language.
SUBJECTS
Twenty out of 36 patients studied initially during
1985-1987 (1) were willing for relavage studies. The
first lavage in these 20 patients was carried out
1.3 ± 0.4 yr after exposure. Relavages were carried
out during 1987-1989 ie. 2.7 ± 0.6 yr after exposure
and they are designated as Group 1 subjects. The
interval between the two lavages was 1.4 ± 0.6 yr. A
new group of 24 patients was also studied during
1988-1991 i.e. 5.1 ± 1.0yr after exposure and is
classified as Group 2. The selection criteria for Group
2 patients were similar to those for the initial study
(1). Briefly, all patients were residents of an area near
the Union Carbide factory (within 5 km) and were
exposed to the toxic gas on the night of December
2-3, 1984. All had respiratory and ophthalmic symp-
toms on the day of exposure and continued to have
respiratory symptoms at the time of evaluation. Main
symptoms were cough, exertional dyspnoea and
chest pain. None of them had any previous cardio-
respiratory disease as assessed intensively by history.
physical examination and skiagram chest. Patients
with the slightest doubt of pre-existing lung disease
were excluded from the study.
CONTROL SUBJECTS
Seventeen non-smoking individuals (age
28.8 ± 8.5 yr) were studied as control subjects for
comparison with BAL cellular profile. They were
unexposed to the toxic gas and were residents of
Madras city. For comparison of BAL fluid fibronec-
tin, 10 non-smoking, normal subjects, not exposed to
the gas and residing at Delhi were evaluated. None of
the control subjects had respiratory symptoms or
abnormal physical findings and all had normal chest
radiographs. Pulmonary function measurements in
control subjects were similar to those of predicted
values (4). None of the normal subjects was on any
medication.
PRE-LAVAGE ASSESSMENT AND INVESTIGATIONS
Pre-lavage assessment and investigations of each
patient included detailed history, physical examina-
tion, a full-plate PA chest roentgenogram a 12 lead
electrocardiogram, total and differential leucocyte
count in the peripheral blood and pulmonary func-
tion tests such as FVC, FEV1 and FEV1/FVC%
(using Transfer Test Model C, PK Morgan Pvt Ltd,
Chatham, U.K.). Patients with pre-existing lung
diseases were excluded from the study.
BRONCHOALVEOLAR LAVAGE
Bronchoscopy and bronchoalveolar lavages (BAL)
were carried out as an outpatient procedure as
Hamidia Hospital, Bhopal, as previously described
(1). In brief, the flexible fibre optic bronchoscope was
passed either transnasally or transorally and the
lavages were done from three subsegments viz. right
middle lobe, lingula and left lower lobe. BAL was
perform d with 300ml sterile 0.9% saline at room
temperature. One hundred millilitres of sterile saline
in five 20 ml aliquots was infused through the fibre
optic bronchoscope into each of the three lobes in the
lower respiratory tract. After each aliquot was
infused, the cells and lavage fluids were recovered by
gentle suction using 50-100 mm H2O negative press-
ure with a clinical suction apparatus and collected
in the specimen traps (Sherwood Medical. Ireland).
The cells recovered by lavage were counted on a
hae ocytometer, using the unconcentrated lavage
fluid (5) and expressed as cells d1-1 of recovered
fluid. The lavage cell differentials were determined
using filtration method (5). Using oil immersion of a
mic oscope,alveolar macrophages, lymphocytes,
neutrophils and eosinophils were identified and 400
cells were counted from each preparation for deriving
the diff rentials by two independent observers and
recorded independently. Both observers agreed to
within 5% of all lavages and the mean value was used
for analysis. Epithelial cells counted were always less
than 5%. Absolute numbers of different types of
cell were derived from total cells times differential
perc ntages.
FIBRONECTIN ESTIMATION
Fibronectin (FN) and albumin in BAL fluid were
estimated in 41 patients including 31 patients from
he initial study (1). Thirty patients had severe expo-
sure and 11 had mild/moderate exposure and the
s verity of exposure was determined as per previously
def ned criteria (1). Ten severely exposed patients and
one mild/moderately exposed patient were smokers.
Ten patients from the initial study had two FN
estimations from two lavages on different occasions.
The interval between the two lavages was
1.6 = 0.7 yr. Fibronectin was measured by simple
radialimmunodiffusion (6) with immunodiffusion
plates (LC Pamigen, Behering Diagnostics, Germany).
Albumin estimation was done by spectrophotometric
method (6). FN in BAL fluid was expressed as
µg mg
-1 albumin.
ANALYSIS
Statistical analysis was done using Mann-Whitney
U-test for independent groups and Wilcoxon Signed
Rank-test for paired observations.
Fibronectin values more than two standard devi-
ations above the mean of normal subjects (i.e.
> 10 µg mg-1 albumin) were classified as abnor-
mally high. Odds ratio was calculated to find the
relative risk of severity of exposure with elevated FN
levels. If either FVC or FEV1 decreased by more than
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10% during the second lavage, patients were charac-
terized as ‘deteriorated’. If none of the parameters
decreased by more than 10% or any parameter
increased by more than 10%, they were classified as
‘no change or improvement’ (7).
Results
GROUP 1 PATIENTS
All patients in this group (n=20) were males. The
mean age was 38.5 ± 9 yr. Three patients continued
to smoke though with reduced intensity, despite
repeated medical advice to quit smoking. Respiratory
symptoms such as cough,  exceptional dyspnoea and
chest pain were persisting in all patients at the time of
the second lavage. Four patients had rales/rhonchi at
initial study. Signs persisted in three and disappeared
in one. However, three developed fresh signs, making
a total of six patients with rales/rhonchi at the time of
the second lavage. Radiographic abnormalities of 1/0
to 2/1 (ILO, 1980 classification) (8) were observed in
nine out of 20 patients. Although there was no
significant difference in pulmonary function measure-
ments (FVC and FEV1) between the first and second
lavages, these continued to be significantly lower
than the normal predicted values (9,10) during the
second lavage (Table 1).
BAL results during the first and second lavages in
Group 1 patients are shown in Table 2. Total inflam-
matory cells (P=0.004) and absolute (total) number
of alveolar macrophages (P=0.003) were significantly
higher in patients compared to normal subjects dur-
ing the first lavage, despite significantly lower fluid
recovery (normal subjects vs. Group 1 patients;
60.1 ± 7.0 ml, 44.6 ± 13.2 ml. P=0.008). During the
second lavage, the total inflammatory cells (P=0.004)
and total macrophages (P=0.002) continued to be
significantly higher than normal subjects. In addition.
there was a significant rise in the neutrophil propor-
tion (P=0.03) and total neutrophils (P=0.03). In
comparison with results of the first lavage, a signifi-
cant rise in neutrophil percentage (P=0.02) and total
neutrophils (P=0.04) was also seen during the second
lavage. There was no significant difference in the fluid
recovery between the first and the second lavage
(44.6 ± 13.2 vs. 48.3 ± 12.4, P>O.2).
GROUP 2 PATIENTS
Of the 24 patients in this group, six were females
and two males were smokers. The mean age was
34.1 ± 9.5 yr. All patients had persistent respiratory
symptoms such as cough, dyspnoea on exertion and
chest pain and three had rhonchi. Radiographic
abnormalities of 1/0 to 2/2 were observed in 15 out of
Table 1 Pulmonary function results
Observed Predicted % Predicted
Group I (n=20)
(a) First BAL
FVC:
FEV1:
FEV1/FVC%
(b) Second BAL
FVC:
FEV1 :
FEV1/FVC%
FEV1
FEV1/FVC%
Control subjects
(n= 17)
FVC:
FEV1:
FEV1/FVC%
3.08* 3.83
± 0.82 ±0.43
2.45* 3.06
± 0.77 ±0.34
79.2 –
± 11.5
3.19* 3.80
± 0.70 ±0.45
2.40* 3.06
± 0.73 ±0.34
74.7 –
± 13.2
3.12** 3.53
± 0.92 ± 0.67
2.46*** 2.82
±0.84 ±0.53
80.5                      –
± 13.3
3.08 3.16
± 0.59 ±0.52
2.70 2.81
± 0.59 ±0.54
87.1 –
± 7.3
80.4
± 19.7
80.0
± 23.0
–
83.3
± 14.0
78.4
± 20.4
–
87.5
± 18.0
87.1
± 25.1
–
97.3
± 12.9
95.2
± 14.8
–
Group 1: Patients with first and second BAL.
Group 1: New series of patients with BAL.
P value, * <0.001, ** <0.01, *** <0.05.
24 patients. FVC and FEV1 were significantly lower
in this group as well as compared to the normal
predicted values (9,10) (Table 1).
The mean values of total inflammatory cells
(P=0.04), total alveolar macrophages (P=0.03), neu-
trophils percentage (P=0.009) and total neutrophils
(P=0.007) were significantly higher in this group of
patients compared to normal subjects (Table 2). The
m an fluid recovery was similar in normal subjects
and patients (normal 60.1 ± 7 ml vs. 56.0 ± 8.8 ml,
P=0.1).
FIBRONECTIN LEVELS
The mean FN level in 10 non-smoking normal
subject  was 6.31 ± .83 µg mg -1 albumin. The
me n FN level in severely exposed patients (n=30),
13.2 ± 11.1 µg mg-1 albumin, was significantly
higher (P=0.04) compared to normal subjects and
this was true when only non-smokers (n=20) were
Normal                                                                                 
Group 1
subjects First lavage Second lavage
(n=17) (n=20) (n=20)
Group 2
(n=24)
15.8 28.0* 31.6* 26.4†
± 6.7 ± 15.2 ± 20.3 ± 20.2
83.9 88.3 87.7 89.4
± 6.4 ± 8.0 ± 7.0 ± 11.0
13.2 25.3* 27.6* 24.1†
± 5.6 ± 15.3 ± 17.8 ± 19.9
14.4 10.2 8.0* 7.1†
±6.4 ± 7.6 ± 5.1 ± 10.0
2.4 2.4 2.6 1.5
± 1.5 ± 2.0- - ±3.3 ± 2.5
0.7 1.1 3.6** 2.1‡
± 0.8 ± 1.4
     0.3
± 4.5 ± 1.8
0.1 1.2** 0.5‡
± 0.1 ± 0.3 ± 2.1 ± 0.6
1.0 0.4 0.8 1.4
± 1.1 ± 1.8 ± 1.6 ± 2.6
0.1 0.1 0.2     0.3
± 0.1 ± 0.4 ± 0.4 ± 0.5
60.1 44.6* 48.3* 56.0
± 7.0 ± 13.2 ± 12.4 ± 8.8
significant difference on FN levels (first lavage
13.0 ± 9.6 µg mg -1 albumin vs. second lavage
13.3 ± 11.8 µg mg -1 albumin, P>0.2) (Table 3). Of
these 10, four had elevated levels during the first
lavage and three continued to have elevated levels
during the second lavage. One patient who had
normal FN during the first lavage had an elevated
level during the second lavage. Another subject with
elevated levels during the first lavage had shown a
reduction to normal values during the second lavage.
Thus, five subjects had elevated FN levels at any one
occasion. Of the five patients who had elevated FN
levels, three had functional deterioration and two
had no change. All were non-smokers. On the other
hand. of the five subjects who had normal FN levels
on both occasions, two deteriorated and one was a
smoker; one unproved and two had no change. Thus,
three of five subjects who had elevated FN at any one
occasion had a decline in pulmonary function,
whereas only one of four subjects (excluding smoker)
Control                   
Exposure Radiology Pulmonary function changes between two lavages (n= 10)
subjects Mild/moderate Severe Normal Abnormal No change Improv ement Deterioration
(n= 10) (n = 11 ) (n = 30) (n= 18) (n=23) (n=4) (n=1) (n=5)
- - -
(a) Mean FN level 6.31 7.0 13.2* 9.8 12.9** –
(µg mg -1 albumin) ± 1.83 ± 2.9 ± 11.1 ± 8.0 ± 11.0
(b) Patients with
Normal FN 10 10 19 15 14 2 2†
Elevated FN 0 1 11† 3 9 2 3
with normal FN on both occasions had a decline in
pulmonary function.
Discussion
The observation that the lower respiratory tract
inflammation has progressed from macrophage
alveolitis to macrophage-neutrophiic alveolitis
2.7 ± 0.6 yr after toxic gas exposure and the finding
of macrophage-neutrophilic alveolitis in a new cohort
of patients during 1988-1991 (5.1 ± 1.0 yr after expo-
sure) suggests that chronic inflammation of the lower
respiratory tract is a feature of toxic gas-induced lung
disease. The fact that alveolar macrophages and
neutrophils are capable of promoting lung injury and
fibrosis (11) suggests the possibility that inhaled toxic
gas may produce permanent damage to pulmonary
parenchyma. Abnormal accumulation of macro-
phages with or without neutrophils has been
described in various chronic lung diseases (12-14)
and also in experimental studies in animals exposed
to asbestos fibres (15,16). It has also been shown in
idiopathic pulmonary fibrosis that activated alveolar
macrophagescan produce neutrophil chemo-
attractants (17.18). Therefore, we believe that the
progression of initial macrophage alveolitis to
macrophage-neutrophic alveolitis represents the
stages in the evolution of ‘toxic gas induced lung
disease’. Thus, the persistence of clinical, radiological
and pulmonary function abnormalities in this study
as well as in previous studies (19-21) may be due
to the consequences of macrophage-neutrophilic
alveolitis.
Abnormally elevated FN levels in BAL fluid were
observed in nearly 30% of patients in this study and a
higher proportion of severely exposed subjects had
elevated FN levels compared to mildly/moderately
exposed. Elevated levels of FN in BAL fluid had been
described in interstitial lung diseases such as sarcoid-
osis and idiopathic pulmonary fibrosis (22-24) and it
had been shown that activated alveolar macrophages
were capable of producing FN (25). Therefore. the
observation of elevated levels of FN in a good
proportion of subjects in this study may suggest
that the expanded numbers of inflammatory cells
especiallyalveolar macrophages areactivated.
Fibronectin along with other mediators had been
shown to contribute to the development of fibrosis by
acting as a chemoattractant to fibroblasts in inter-
stitial lung diseases (11,25). Therefore, the findings of
elevated levels of FN in BAL fluid with macrophage-
neutrophilic alveolitis may suggest that some of these
patients may develop lung fibrosis. This has been
further corroborated by the observation that three of
five non-smoking subjects who had elevated FN
levels at any one point of time had a decline in
pulmonary function. In conformity with this, pul-
monary fibrosis had been demonstrated by com-
puterized tomography (CT) in a toxic gas exposed
victim (26) and in experimental animals exposed to
methyl isocyanate (27).
As some of the patients exposed to toxic gas at
Bhopal are having persistent respiratory symptoms,
roentgenographic abnormalities and ventilatory
def cts as evidenced by significantly reduced pul-
monary function values even 5 yr after exposure, the
p rsisting alveolitis may result in further functional
lung derangements that may lead to respiratory
c ippling. Therefore preventive and rehabilitative
modalities of treatment for suppression of alveolitis
are needed in this population.
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